The Progranulin pipeline drugs market research report outlays comprehensive information on the Progranulin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Progranulin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System, and Oncology which include the indications Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis, Ovarian Cancer, and Non-Small Cell Lung Cancer. It also reviews key players involved in Progranulin targeted therapeutics development with respective active and dormant or discontinued products.
The Progranulin pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 1, 2, and 2 respectively.
Progranulin overview
Progranulin (GRN) acts as a key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing, and cell proliferation. GRN modulates inflammation in neurons by preserving neuron survival, axonal outgrowth, and neuronal integrity. It also promotes epithelial cell proliferation by blocking TNF-mediated neutrophil activation, preventing the release of oxidants and proteases.
For a complete picture of Progranulin’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.